CA2723314C - Templated open flocs of anisotropic particles for enhanced pulmonary delivery - Google Patents

Templated open flocs of anisotropic particles for enhanced pulmonary delivery Download PDF

Info

Publication number
CA2723314C
CA2723314C CA2723314A CA2723314A CA2723314C CA 2723314 C CA2723314 C CA 2723314C CA 2723314 A CA2723314 A CA 2723314A CA 2723314 A CA2723314 A CA 2723314A CA 2723314 C CA2723314 C CA 2723314C
Authority
CA
Canada
Prior art keywords
particles
hfa
tff
templated
itz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2723314A
Other languages
English (en)
French (fr)
Other versions
CA2723314A1 (en
Inventor
Keith P. Johnston
Joshua Engstrom
Jasmine Tam
Robert O. Williams Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA2723314A1 publication Critical patent/CA2723314A1/en
Application granted granted Critical
Publication of CA2723314C publication Critical patent/CA2723314C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2723314A 2008-02-13 2009-02-13 Templated open flocs of anisotropic particles for enhanced pulmonary delivery Active CA2723314C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2821808P 2008-02-13 2008-02-13
US61/028,218 2008-02-13
PCT/US2009/034162 WO2009103035A2 (en) 2008-02-13 2009-02-13 Templated open flocs of anisotropic particles for enhanced pulmonary delivery

Publications (2)

Publication Number Publication Date
CA2723314A1 CA2723314A1 (en) 2009-08-20
CA2723314C true CA2723314C (en) 2017-01-10

Family

ID=40955349

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2723314A Active CA2723314C (en) 2008-02-13 2009-02-13 Templated open flocs of anisotropic particles for enhanced pulmonary delivery

Country Status (7)

Country Link
US (7) US12263243B2 (https=)
EP (1) EP2252275B1 (https=)
AU (1) AU2009214443B2 (https=)
CA (1) CA2723314C (https=)
DK (1) DK2252275T3 (https=)
NO (1) NO2252275T3 (https=)
WO (1) WO2009103035A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2252275T3 (https=) 2008-02-13 2018-04-28
CA2754691C (en) 2009-03-26 2019-07-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US8506799B2 (en) * 2009-09-09 2013-08-13 ClearCorp Suspended particle characterization system for a water processing facility
US9248110B2 (en) 2010-03-18 2016-02-02 Steven Lehrer Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
US20110229418A1 (en) * 2010-03-18 2011-09-22 Steven Lehrer Compositions and Methods of Treating and Preventing Lung Cancer
US9228785B2 (en) 2010-05-04 2016-01-05 Alexander Poltorak Fractal heat transfer device
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP3470057B1 (en) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Cationic dry powders comprising magnesium salt
RU2017144619A (ru) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN104274427A (zh) * 2013-07-03 2015-01-14 陆克塞纳医药公司 格拉司琼气溶胶组合物及其用途
CN104274426A (zh) * 2013-07-03 2015-01-14 陆克塞纳医药公司 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途
US10307370B2 (en) 2013-10-08 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
ES2922206T3 (es) 2014-02-20 2022-09-09 Otitopic Inc Formulaciones de polvo seco para la inhalación
DK3125875T3 (da) 2014-04-04 2023-07-24 Ai Therapeutics Inc Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
ES2942297T3 (es) 2014-07-31 2023-05-31 Vectura Inc Formulaciones de polvo seco para inhalación
KR20170095807A (ko) 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
JP6940416B2 (ja) * 2015-05-01 2021-09-29 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 多剤脆性マトリックス組成物
EA201890618A1 (ru) 2015-09-01 2018-10-31 Ферст Вэйв Байо, Инк. Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
EP3440019A4 (en) * 2016-04-08 2019-02-13 Remirez, Jose, Antonio SYSTEM AND METHOD FOR AUTOMATED DOSAGE WITH LIGHT PROFILING FOR WASTEWATER FILTRATION SYSTEM
EP3485215B1 (en) 2016-07-12 2023-06-07 Alexander Poltorak System and method for maintaining efficiency of a heat sink
EP3525759A1 (en) 2016-10-14 2019-08-21 Pulmatrix Operating Company, Inc. Antifungal dry powders
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
WO2019204568A1 (en) * 2018-04-20 2019-10-24 Board Of Regents, The University Of Texas System Apparatus and methods for characterizing plume geometry
US12091313B2 (en) 2019-08-26 2024-09-17 The Research Foundation For The State University Of New York Electrodynamically levitated actuator
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
TW202200121A (zh) 2020-03-16 2022-01-01 美商費斯特威弗生技股份有限公司 治療方法
US12076328B2 (en) 2020-04-01 2024-09-03 Board Of Regents, The University Of Texas System Pharmaceutical compositions of niclosamide
EP4138791A1 (en) * 2020-04-20 2023-03-01 Board of Regents, The University of Texas System Biologically active dry powder compositions and method of their manufacture and use
WO2021242675A1 (en) 2020-05-26 2021-12-02 Gradalis, Inc. Methods for the treatment of viral respiratory infections
WO2022055817A1 (en) 2020-09-09 2022-03-17 Gradalis, Inc. Composition formulated into inhalable dosage forms for the treatment of lung|tumors
CA3219943A1 (en) 2021-05-12 2022-11-17 Tff Pharmaceuticals, Inc. Dry powder formulations of tacrolimus for administration by inhalation once daily (qd)
JP2024534185A (ja) * 2021-08-30 2024-09-18 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム モノクローナル抗体乾燥粉末
US20230112800A1 (en) 2021-08-31 2023-04-13 Board Of Regents, The University Of Texas System Delayed release niclosamide formulation
WO2024059819A2 (en) 2022-09-15 2024-03-21 Tff Pharmaceuticals, Inc. Compositions of cannabinoids for delivery by inhalation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
JPH1112197A (ja) 1997-06-18 1999-01-19 Cosmo Sogo Kenkyusho:Kk 悪性腫瘍診断剤及び治療剤
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
AR028746A1 (es) 2000-06-23 2003-05-21 Norton Health Care Ltd Cartucho de dosis previamente medidas para inhalador de polvo seco accionado por la respiracion, el inhalador y un metodo de provision de dosis previamente medidas de polvo seco
JP2003146523A (ja) 2001-11-15 2003-05-21 Canon Inc 画像形成装置
EP1501483A2 (en) 2002-04-25 2005-02-02 Nektar Therapeutics UK Ltd Particulate materials
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
WO2004030659A1 (en) 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
MXPA05007156A (es) * 2002-12-31 2005-09-21 Nektar Therapeutics Formulacion farmaceuticas aerosolizable para terapia para infecciones fungicas.
EP1589948A1 (en) 2003-01-15 2005-11-02 Dow Global Technologies Inc. Drug particles obtained by freezing onto a cold surface
CA2538237A1 (en) 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
CN101687044B (zh) * 2007-05-25 2014-10-29 不列颠哥伦比亚大学 用于口服给药的治疗剂的制剂和相关方法
NO2252275T3 (https=) * 2008-02-13 2018-04-28

Also Published As

Publication number Publication date
US11364197B2 (en) 2022-06-21
EP2252275A4 (en) 2013-11-06
US20090208582A1 (en) 2009-08-20
WO2009103035A3 (en) 2009-11-12
EP2252275A2 (en) 2010-11-24
WO2009103035A2 (en) 2009-08-20
US20250127717A1 (en) 2025-04-24
US20200069572A1 (en) 2020-03-05
DK2252275T3 (en) 2018-03-05
US10434062B2 (en) 2019-10-08
US20220354778A1 (en) 2022-11-10
NO2252275T3 (https=) 2018-04-28
US20190117557A1 (en) 2019-04-25
AU2009214443A1 (en) 2009-08-20
EP2252275B1 (en) 2017-11-29
US12029816B2 (en) 2024-07-09
US20210007971A1 (en) 2021-01-14
AU2009214443B2 (en) 2013-10-10
US10660850B2 (en) 2020-05-26
CA2723314A1 (en) 2009-08-20
US20100221343A1 (en) 2010-09-02
US12263243B2 (en) 2025-04-01
US10092512B2 (en) 2018-10-09

Similar Documents

Publication Publication Date Title
US12029816B2 (en) Compositions and methods of making brittle-matrix particles through blister pack freezing
Williams III A. M. Johnston
US6946117B1 (en) Stabilized preparations for use in nebulizers
CA2304973C (en) Stabilized preparations for use in nebulizers
EP1734938B1 (en) Insulin highly respirable microparticles
Lin et al. Powder production and particle engineering for dry powder inhaler formulations
Tam et al. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution
AU770529B2 (en) Pharmaceutical aerosol composition containing HFA 227 and HFA 134a
Ostrander et al. An in-vitro assessment of a NanoCrystal™ beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization
US20080038357A1 (en) Inhalation Powder Containing the CGRP antagonist BIBN4096 and Process for the Preparation Thereof
Engstrom et al. Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers
Chan Inhalation drug delivery devices and emerging technologies
JP2008511637A (ja) 致命的な感染症を治療する薬剤組成物の増強された供給
Rowe et al. Compositions and methods of making brittle-matrix particles through blister pack freezing
AU2003208862A1 (en) Powder inhalation containing cgrp-antagonist bibn4096 and method for the production thereof
Durham et al. Spray dried pyrazinoate salts for tuberculosis therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251202

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260316

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260316